PDF herunterladen
Thromb Haemost 1992; 67(06): 644-648
DOI: 10.1055/s-0038-1648516
Original Articles
Schattauer GmbH Stuttgart

A Novel Sensitive Assay for Functional Factor XII Based on the Generation of Kallikrein-C1-lnhibitor Complexes in Factor Xll-Deficient Plasma by Glass-Bound Factor XII

D M Dors
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
J H Nuijens
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
C C M Huijbregts
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
,
C E Hack
The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 09. Oktober 1991

Accepted after revision 08. Januar 1992

Publikationsdatum:
03. Juli 2018 (online)

  als PDF herunterladen  Lizenzen und Reprints

Summary

We developed a very sensitive assay for functional factor XII. This assay is based on the property of glass-bound factor XII to activate prekallikrein (PK) into kallikrein in factor XH-deficient plasma, which is assessed by measuring the formation of kallikrein- C1 -inhibitor complexes in this plasma by radioimmunoassay.

Incubation of varying amounts of factor XII in glass tubes led to a dose-dependent increase in kallikrein-C1-inhibitor complexes in factor XH-deficient plasma with a lower limit of detection of ± 20 pg of factor XII. The specificity of the assay for factor XII was demonstrated by experiments with plasmas deficient for factor XII, PK or high molecular weight kininogen (HK) and by incubation of factor XII with Polybrene or with a monoclonal antibody that inhibits the amidolytic and procoagulant activity of factor XII. The high sensitivity of the assay appeared to be due to the inability of Cl-inhibitor to inhibit factor XII bound to glass, which resulted in a molar ratio of generated kallikrein to glass-bound factor XII of at least 100:1.

This assay for factor XII may be a feasible tool in studies on structural and functional aspects of (recombinant) factor XII species synthesized by cultured cells.

 

  • References

  • 1 Kaplan AP. The intrinsic coagulation, fibrinolytic and kinin-forming pathways of man. In: Textbook of Rheumatology. Kelley WN, Harris ED, Ruddy S, Sledge CB. eds WB Saunders; Philadelphia, PA: 1985. pp 95-114
    Google Scholar
  • 2 Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-15
    PubMedGoogle Scholar
  • 3 Tans G, Rosing J. Structural and functional characterisation of factor XII. In: Seminars in Thrombosis and Hemostasis. Mammen EF, Mannhalter CH, Murano G, Bick RL. eds Thieme Medical Publishers, Inc; New York: 1987. 13th edn. pp 1-14
    Google Scholar
  • 4 Tans G, Griffin JH. Properties of sulfatides in factor-XII-dependent contact activation. Blood 1982; 59: 69-75
    PubMedGoogle Scholar
  • 5 Espana F, Ratnoff OD. Activation of Hageman factor by sulfatides and other agents in the absence of plasma proteases. J Lab Clin Med 1983; 102: 31-45
    PubMedGoogle Scholar
  • 6 Tans G, Rosing J, Griffin JH. Sulfatide-dependent autoactivation of human blood coagulation factor XII (Hageman Factor). J Biol Chem 1983; 258: 8215-8222
    PubMedGoogle Scholar
  • 7 Cochrane CG, Revak SD, Aiken BS, Wuepper KD. The structural characteristics and activation of Hageman factor. In: Inflammation: Mechanism and Control. Lepow IH, Ward PA. eds Academic £ress; New York: 1972. pp 119-138
    Google Scholar
  • 8 Walsh PN, Griffin JH. Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood 1981; 57: 106-118
    PubMedGoogle Scholar
  • 9 Bouma BN, Miles LA, Beretta G, Griffin JH. Human plasma prekallikrein. Study of its activation by activated factor XII and its inactivation by diisopropyl phosphofluoridate. Biochemistry 1980; 19: 1151-1160
    CrossrefPubMedGoogle Scholar
  • 10 Revak SD, Cochrane CG, Griffin JH. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest 1977; 59: 1167-1175
    CrossrefPubMedGoogle Scholar
  • 11 Cochrane CG, Revak SD, Wuepper KD. Activation of Hageman factor in solid and fluid phases. J Exp Med 1973; 138: 1564-1583
    CrossrefPubMedGoogle Scholar
  • 12 Tankersley DL, Finlayson JS. Kinetics of activation and autoactivation of human factor XII. Biochemistry 1984; 23: 273-279
    CrossrefPubMedGoogle Scholar
  • 13 Mandle RJr, Colman RW, Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976; 73: 4179-4183
    CrossrefPubMedGoogle Scholar
  • 14 Thompson RE, Mandle RJr, Kaplan AP. Association of Factor XI and High Molecular Weight Kininogen in Human Plasma. J Clin Invest 1977; 60: 1376-1380
    CrossrefPubMedGoogle Scholar
  • 15 Griffin JH, Cochrane CG. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci USA 1976; 73: 2554-2558
    CrossrefPubMedGoogle Scholar
  • 16 Saito H, Ratnoff OD, Pensky J. Radioimmunoassay of human Hageman factor (factor XII). J Lab Clin Med 1976; 88: 506-514
    PubMedGoogle Scholar
  • 17 Nuijens JH, Huijbregts CCM, Eerenberg AJM, Abbink JJ. Strack van Schijndel RJM, Felt-Bersma RJF, Thijs LG, Hack CE. Quantification of plasma factor XII a-Cl-Inhibitor and kallikrein-Cl-Inhibitor complexes in sepsis. Blood 1988; 72: 1841-1848
    PubMedGoogle Scholar
  • 18 Nuijens JH, Huijbregts CCM, Eerenberg-Belmer AJM, Meijers JCM, Bouma BN, Hack CE. Activation of the contact system of coagulation by a monoclonal antibody directed against a neodeterminant in the heavy chain region of human coagulation factor XII (Hageman Factor). J Biol Chem 1989; 264: 12941-12949
    CrossrefPubMedGoogle Scholar
  • 19 Kaplan AP, Gruber B, Harpel PC. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-Cl inactivator complexes by an enzyme-linked differential antibody immunosorbent assay. Blood 1985; 66: 636-641
    PubMedGoogle Scholar
  • 20 Nuijens JH, Huijbregts CCM, Cohen M, Navis GO, de Vries A, Eerenberg AJM, Bakker JC, Hack CE. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-Cl-Inhibitor and kallikrein-Cl-Inhibitor complexes by specific radioimmunoassays. Thromb Haemostas 1987; 58: 778-785
    PubMedGoogle Scholar
  • 21 Proctor RR, Rapaport S. The partial thromboplastin time with kaolin: A simple screening test for first stage plasma clotting deficiencies. Am J Clin Pathol 1961; 35: 212-219
    PubMedGoogle Scholar
  • 22 Tankersley DL, Alving BM, Finlayson JS. Activation of factor XII by dextran sulfate: The basis for an assay of factor XII. Blood 1983; 62: 448-456
    PubMedGoogle Scholar
  • 23 Kerbiriou DM, Griffin JH. Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma. J Biol Chem 1979; 254: 12020-12027
    PubMedGoogle Scholar
  • 24 Nuijens JH, Eerenberg-Belmer AJM, Huijbregts CCM, Schreuder WO, Felt’-Bersma RJF, Abbink JJ, Thijs LG, Hack CE. Proteolytic inactivation of plasma Cl-Inhibitor in sepsis. J Clin Invest 1989; 84: 443550
    PubMedGoogle Scholar
  • 25 Patstoii PA, Gettins P, Beechem J, Schapira M. Mechanism of serpin action: evidence that Cl inhibitor functions as a suicide substrate. Biochemistry 1991; 30: 8876-8882
    CrossrefPubMedGoogle Scholar
  • 26 Ratnoff OD, Pensky J, Ogston D, Naff GB. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C’lr subcomponent of the first component of complement by serum C’l esterase inhibitor. J Exp Med 1969; 129: 315-329
    CrossrefPubMedGoogle Scholar
  • 27 Connell DJ. Inhibitors of kallikrein in human plasma. J Clin Invest 1972; 51: 1611-1623
    CrossrefPubMedGoogle Scholar
  • 28 Gigli I, Mason JW, Colman RW, Austen KF. Interaction of plasma kallikrein with the Cl-inhibitor. J Immunol 1970; 104: 574-581
    PubMedGoogle Scholar
  • 29 Pixley RA, Schmaier A, Colman RW. Effect of negatively charged activating compounds on inactivation of factor XII a by Cl inhibitor. Arch Biochem Biophys 1987; 256: 490-498
    CrossrefPubMedGoogle Scholar
  • 30 Lewin MF, Kaplan AP, Harpel PC. Studies of Cl inactivator-plasma kallikrein complexes in purified systems and in plasma. Quantification by an enzyme-linked differential antibody immunosorbent assay. J Biol Chem 1983; 258: 6415-6421
    PubMedGoogle Scholar
  • 31 van der Graaf F, Keus FJA, Vlooswijk RAA, Bouma BN. The contact activation mechanism in human plasma: activation induced by dextran sulfate. Blood 1982; 59: 1225-1233
    PubMedGoogle Scholar
  • 32 Scott CF, Schapira M, James HL, Cohen AB, Colman RW. Inactivation of factor XI a by plasma protease inhibitors. Predominant role of al-protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest 1982; 69: 844-852
    CrossrefPubMedGoogle Scholar
  • 33 Walsh PN, Sinha D, Kueppers F, Seaman FS. Platelets protect factor XI a from inactivation by and complex formation with alpha-1-protease inhibitor. Circulation 1986; 74: 11-93
    PubMedGoogle Scholar
  • 34 Schapira M, Scott CF, Colman RW. Protection of human kallikrein from inactivation by Cl inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry 1981; 20: 2738-2743
    CrossrefPubMedGoogle Scholar
  • 35 Mariniak E. Factor-Xa inactivation by antithrombin III: evidence for biological stabilization of factor Xa by factor V-phospholipid complex. Br J Haematol 1973; 24: 391-400
    CrossrefPubMedGoogle Scholar
  • 36 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
    CrossrefPubMedGoogle Scholar